BRCA-话题@MedSci

#BRCA#

135篇内容 | 2981人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594040, encodeId=2f01159404070, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Lynparza治疗复发性BRCA突变的卵巢癌效果显著, objectType=article, longId=156434, objectId=9ae6156434a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ae6156434a1, replyNumber=0, likeNumber=66, createdTime=2018-12-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ae6156434a1, moduleTitle=Lynparza治疗复发性BRCA突变的卵巢癌效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ae6156434a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594039, encodeId=b8991594039cd, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=【2018 ESMO ASIA】SOLO1研究：BRCA突变卵巢癌患者一线维持治疗结果喜人, objectType=article, longId=154850, objectId=6a581548506d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a581548506d, replyNumber=0, likeNumber=77, createdTime=2018-12-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a581548506d, moduleTitle=【2018 ESMO ASIA】SOLO1研究：BRCA突变卵巢癌患者一线维持治疗结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a581548506d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594038, encodeId=821a159403825, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=新发现：奥拉帕利让BRCA突变患者疾病进展或死亡风险降低70%, objectType=article, longId=151732, objectId=8271151e328a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8271151e328a, replyNumber=0, likeNumber=54, createdTime=2018-10-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8271151e328a, moduleTitle=新发现：奥拉帕利让BRCA突变患者疾病进展或死亡风险降低70%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8271151e328a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594037, encodeId=abf3159403e1f, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Nature：BRCA1突变真是乳腺和卵巢的“致癌炸弹”吗？科学家利用CRISPR终于揭开了数千种变异的意义, objectType=article, longId=151484, objectId=538015148427, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=538015148427, replyNumber=0, likeNumber=58, createdTime=2018-10-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=538015148427, moduleTitle=Nature：BRCA1突变真是乳腺和卵巢的“致癌炸弹”吗？科学家利用CRISPR终于揭开了数千种变异的意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=538015148427)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594036, encodeId=42d7159403656, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=JAMA Network Open：BRCA基因检测应该面向所有女性, objectType=article, longId=150537, objectId=20eb15053e05, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20eb15053e05, replyNumber=0, likeNumber=68, createdTime=2018-10-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20eb15053e05, moduleTitle=JAMA Network Open：BRCA基因检测应该面向所有女性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20eb15053e05)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594035, encodeId=4c6515940356f, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=JCO：Lurbinectedin治疗BRCA突变转移性乳腺癌, objectType=article, longId=149919, objectId=11e714991947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11e714991947, replyNumber=0, likeNumber=62, createdTime=2018-09-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11e714991947, moduleTitle=JCO：Lurbinectedin治疗BRCA突变转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11e714991947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594034, encodeId=88fb159403451, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=NEJM：talazoparib治疗BRCA 1/2突变阳性乳腺癌, objectType=article, longId=146767, objectId=a57b146e67dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a57b146e67dd, replyNumber=0, likeNumber=61, createdTime=2018-08-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a57b146e67dd, moduleTitle=NEJM：talazoparib治疗BRCA 1/2突变阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a57b146e67dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594033, encodeId=abce1594033de, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Brit J Cancer：IVF卵巢刺激与BRCA1/2突变携带者原发性乳腺癌风险！, objectType=article, longId=141707, objectId=f022141e0757, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f022141e0757, replyNumber=0, likeNumber=81, createdTime=2018-06-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f022141e0757, moduleTitle=Brit J Cancer：IVF卵巢刺激与BRCA1/2突变携带者原发性乳腺癌风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f022141e0757)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594032, encodeId=f91015940327d, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=基于下一代测序技术的BRCA基因检测流程中国专家共识, objectType=article, longId=140941, objectId=c34814094154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c34814094154, replyNumber=0, likeNumber=39, createdTime=2018-06-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c34814094154, moduleTitle=基于下一代测序技术的BRCA基因检测流程中国专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c34814094154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594031, encodeId=c2951594031ab, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=2018 南亚实践共识建议：BRCA检测时机, objectType=article, longId=138257, objectId=00a913825e56, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a913825e56, replyNumber=0, likeNumber=30, createdTime=2018-05-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a913825e56, moduleTitle=2018 南亚实践共识建议：BRCA检测时机, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a913825e56)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594030, encodeId=7cb415940306a, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, objectType=article, longId=137196, objectId=7db713e1967a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7db713e1967a, replyNumber=0, likeNumber=60, createdTime=2018-05-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7db713e1967a, moduleTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7db713e1967a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594029, encodeId=11e9159402917, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌风险！, objectType=article, longId=134108, objectId=35eb134108f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35eb134108f7, replyNumber=0, likeNumber=70, createdTime=2018-04-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35eb134108f7, moduleTitle=Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35eb134108f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594028, encodeId=bedb1594028e8, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Lancet Onco：希望！新药治疗复发性BRCA卵巢癌可产显著持久抗肿瘤活性！, objectType=article, longId=127553, objectId=9fd512e553f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fd512e553f9, replyNumber=0, likeNumber=69, createdTime=2018-01-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fd512e553f9, moduleTitle=Lancet Onco：希望！新药治疗复发性BRCA卵巢癌可产显著持久抗肿瘤活性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fd512e553f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594027, encodeId=3a3a159402e5d, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=ANN ONCOL：局部复发或转移性BRCA1/2乳腺癌患者治疗方案比较, objectType=article, longId=127478, objectId=90d712e4782d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90d712e4782d, replyNumber=0, likeNumber=50, createdTime=2018-01-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90d712e4782d, moduleTitle=ANN ONCOL：局部复发或转移性BRCA1/2乳腺癌患者治疗方案比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90d712e4782d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594026, encodeId=279c15940266f, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌发生风险之间的关系, objectType=article, longId=127217, objectId=36f312e21700, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36f312e21700, replyNumber=0, likeNumber=34, createdTime=2018-01-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36f312e21700, moduleTitle=Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌发生风险之间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36f312e21700)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594025, encodeId=58d615940254d, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=美国FDA批准奥拉帕利用于治疗携带BRCA基因突变的 HER2阴性转移性乳腺癌患者, objectType=article, longId=126913, objectId=7292126913f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7292126913f3, replyNumber=0, likeNumber=60, createdTime=2018-01-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7292126913f3, moduleTitle=美国FDA批准奥拉帕利用于治疗携带BRCA基因突变的 HER2阴性转移性乳腺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7292126913f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594024, encodeId=925f159402423, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Lancet Oncol：BRCA突变并不影响乳腺癌患者生存率！双乳切除未必真的获益！并不影响乳腺癌患者生存率！双乳切除未必真的获益！, objectType=article, longId=126699, objectId=2beb1266996f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2beb1266996f, replyNumber=0, likeNumber=68, createdTime=2018-01-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2beb1266996f, moduleTitle=Lancet Oncol：BRCA突变并不影响乳腺癌患者生存率！双乳切除未必真的获益！并不影响乳腺癌患者生存率！双乳切除未必真的获益！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2beb1266996f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594023, encodeId=d44f159402359, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, objectType=article, longId=124749, objectId=622e124e49ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=622e124e49ed, replyNumber=0, likeNumber=57, createdTime=2017-12-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=622e124e49ed, moduleTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=622e124e49ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594022, encodeId=ea821594022b6, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Matulonis教授：PARP抑制剂——BRCA相关癌症的克星, objectType=article, longId=123424, objectId=07e11234248f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07e11234248f, replyNumber=0, likeNumber=68, createdTime=2017-12-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07e11234248f, moduleTitle=Matulonis教授：PARP抑制剂——BRCA相关癌症的克星, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07e11234248f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594021, encodeId=2af2159402185, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Nat Commun：新研究揭示BRCA癌细胞最后的“生存策略”, objectType=article, longId=122248, objectId=235e12224865, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=235e12224865, replyNumber=0, likeNumber=39, createdTime=2017-12-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=235e12224865, moduleTitle=Nat Commun：新研究揭示BRCA癌细胞最后的“生存策略”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=235e12224865)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRCA

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Lynparza治疗复发性BRCA突变的卵巢癌效果显著

2018-12-24

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

【2018 ESMO ASIA】SOLO1研究：BRCA突变卵巢癌患者一线维持治疗结果喜人

2018-12-02

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

新发现：奥拉帕利让BRCA突变患者疾病进展或死亡风险降低70%

2018-10-25

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Nature：BRCA1突变真是乳腺和卵巢的“致癌炸弹”吗？科学家利用CRISPR终于揭开了数千种变异的意义

2018-10-22

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

JAMA Network Open：BRCA基因检测应该面向所有女性

2018-10-09

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

JCO：Lurbinectedin治疗BRCA突变转移性乳腺癌

2018-09-30

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

NEJM：talazoparib治疗BRCA 1/2突变阳性乳腺癌

2018-08-18

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Brit J Cancer：IVF卵巢刺激与BRCA1/2突变携带者原发性乳腺癌风险！

2018-06-28

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

基于下一代测序技术的BRCA基因检测流程中国专家共识

2018-06-18

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

2018 南亚实践共识建议：BRCA检测时机

2018-05-17

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究

2018-05-05

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌风险！

2018-04-04

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Lancet Onco：希望！新药治疗复发性BRCA卵巢癌可产显著持久抗肿瘤活性！

2018-01-26

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

ANN ONCOL：局部复发或转移性BRCA1/2乳腺癌患者治疗方案比较

2018-01-25

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Ann Intern Med：白细胞BRCA1启动子甲基化状态与卵巢癌发生风险之间的关系

2018-01-23

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

美国FDA批准奥拉帕利用于治疗携带BRCA基因突变的 HER2阴性转移性乳腺癌患者

2018-01-20

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Lancet Oncol：BRCA突变并不影响乳腺癌患者生存率！双乳切除未必真的获益！并不影响乳腺癌患者生存率！双乳切除未必真的获益！

2018-01-18

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验

2017-12-28

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Matulonis教授：PARP抑制剂——BRCA相关癌症的克星

2017-12-16

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Nat Commun：新研究揭示BRCA癌细胞最后的“生存策略”

2017-12-06

科室
- - 订阅+
  - 更多科室
工具
服务